Biomarin Pharmaceutical Inc [NASDAQ: BMRN] surged by $0.81 during the normal trading session on Monday and reaching a high of $56.13 during the day while it closed the day at $55.5.
Biomarin Pharmaceutical Inc stock has also gained 1.91% of its value over the past 7 days. However, BMRN stock has declined by -3.39% in the 3 months of the year. Over the past six months meanwhile, it has lost -4.49% and lost -11.29% year-on date.
The market cap for BMRN stock reached $10.66 billion, with 192.10 million shares outstanding and 189.22 million shares in the current float. Compared to the average trading volume of 2.32M shares, BMRN reached a trading volume of 17330090 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Biomarin Pharmaceutical Inc [BMRN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMRN shares is $89.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMRN stock is a recommendation set at 1.61. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Biomarin Pharmaceutical Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 06, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Neutral. The new note on the price target was released on September 08, 2025, representing the official price target for Biomarin Pharmaceutical Inc stock. Previously, the target price had yet another raise to $85, while Raymond James analysts kept a Outperform rating on BMRN stock.
The Price to Book ratio for the last quarter was 1.76, with the Price to Cash per share for the same quarter was set at 7.69. Price to Free Cash Flow for BMRN in the course of the last twelve months was 12.81 with Quick ratio for the last quarter at 3.10.
BMRN stock trade performance evaluation
Biomarin Pharmaceutical Inc [BMRN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.91. With this latest performance, BMRN shares gained by 1.87% in over the last four-week period, additionally sinking by -4.49% over the last 6 months – not to mention a drop of -15.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMRN stock in for the last two-week period is set at 57.92, with the RSI for the last a single of trading hit 1.75, and the three-weeks RSI is set at 1.68 for Biomarin Pharmaceutical Inc [BMRN]. The present Moving Average for the last 50 days of trading for this stock 53.70, while it was recorded at 53.88 for the last single week of trading, and 59.19 for the last 200 days.
Biomarin Pharmaceutical Inc [BMRN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biomarin Pharmaceutical Inc [BMRN] shares currently have an operating margin of 27.73% and a Gross Margin at 80.64%. Biomarin Pharmaceutical Inc’s Net Margin is presently recorded at 16.87%.
Biomarin Pharmaceutical Inc (BMRN) Capital Structure & Debt Analysis
According to recent financial data for Biomarin Pharmaceutical Inc. ( BMRN), the Return on Equity (ROE) stands at 9.07%, suggesting modest shareholder returns. The Return on Assets (ROA) is 7.20%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Biomarin Pharmaceutical Inc’s Return on Invested Capital (ROIC) is 7.82%, showcasing its effectiveness in deploying capital for earnings.
Biomarin Pharmaceutical Inc (BMRN) Efficiency & Liquidity Metrics
Based on Biomarin Pharmaceutical Inc’s (BMRN) latest financial statements, the Debt-to-Equity Ratio is 0.10%, indicating its reliance on debt financing relative to shareholder equity.
Biomarin Pharmaceutical Inc (BMRN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Biomarin Pharmaceutical Inc. (BMRN) effectively leverages its workforce, generating an average of $171190.79 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.83% and a Quick Ratio of 3.10%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Biomarin Pharmaceutical Inc [BMRN] stock
With the latest financial reports released by the company, Biomarin Pharmaceutical Inc posted 0.92/share EPS, while the average EPS was predicted by analysts to be reported at 0.74/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.18. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biomarin Pharmaceutical Inc go to 33.01%.
Biomarin Pharmaceutical Inc [BMRN]: Institutional Ownership
There are presently around $97.99%, or 98.76%% of BMRN stock, in the hands of institutional investors. The top three institutional holders of BMRN stocks are: BLACKROCK INC. with ownership of 22.74 million shares, which is approximately 11.9604%. VANGUARD GROUP INC, holding 18.99 million shares of the stock with an approximate value of $$1.56 billion in BMRN stocks shares; and VANGUARD GROUP INC, currently with $$1.55 billion in BMRN stock with ownership which is approximately 9.8836%.
